General investigated for emails to Petraeus friend
















PERTH, Australia (AP) — In a new twist to the Gen. David Petraeus sex scandal, the Pentagon said Tuesday that the top American commander in Afghanistan, Gen. John Allen, is under investigation for alleged “inappropriate communications” with a woman who is said to have received threatening emails from Paula Broadwell, the woman with whom Petraeus had an extramarital affair.


Defense Secretary Leon Panetta said in a written statement issued to reporters aboard his aircraft, en route from Honolulu to Perth, Australia, that the FBI referred the matter to the Pentagon on Sunday.













Panetta said that he ordered a Pentagon investigation of Allen on Monday.


A senior defense official traveling with Panetta said Allen’s communications were with Jill Kelley, who has been described as an unpaid social liaison at MacDill Air Force Base, Fla., which is headquarters to the U.S. Central Command. She is not a U.S. government employee.


Kelley is said to have received threatening emails from Broadwell, who is Petraeus’ biographer and who had an extramarital affair with Petraeus that reportedly began after he became CIA director in September 2011.


Petraeus resigned as CIA director on Friday.


Allen, a four-star Marine general, succeeded Petraeus as the top American commander in Afghanistan in July 2011.


The senior official, who discussed the matter only on condition of anonymity because it is under investigation, said Panetta believed it was prudent to launch a Pentagon investigation, although the official would not explain the nature of Allen’s problematic communications.


The official said 20,000 to 30,000 pages of emails and other documents from Allen’s communications with Kelley between 2010 and 2012 are under review. He would not say whether they involved sexual matters or whether they are thought to include unauthorized disclosures of classified information. He said he did not know whether Petraeus is mentioned in the emails.


“Gen. Allen disputes that he has engaged in any wrongdoing in this matter,” the official said. He said Allen currently is in Washington.


Panetta said that while the matter is being investigated by the Defense Department Inspector General, Allen will remain in his post as commander of the International Security Assistance Force, based in Kabul. He praised Allen as having been instrumental in making progress in the war.


The FBI’s decision to refer the Allen matter to the Pentagon rather than keep it itself, combined with Panetta’s decision to allow Allen to continue as Afghanistan commander without a suspension, suggested strongly that officials viewed whatever happened as a possible infraction of military rules rather than a violation of federal criminal law.


Allen was Deputy Commander of Central Command, based in Tampa, prior to taking over in Afghanistan. He also is a veteran of the Iraq war.


In the meantime, Panetta said, Allen’s nomination to be the next commander of U.S. European Command and the commander of NATO forces in Europe has been put on hold “until the relevant facts are determined.” He had been expected to take that new post in early 2013, if confirmed by the Senate, as had been widely expected.


Panetta said President Barack Obama was consulted and agreed that Allen’s nomination should be put on hold. Allen was to testify at his confirmation hearing before the Senate Armed Services Committee on Thursday. Panetta said he asked committee leaders to delay that hearing.


NATO officials had no comment about the delay in Allen’s appointment.


“We have seen Secretary Panetta‘s statement,” NATO spokeswoman Carmen Romero said in Brussels. “It is a U.S. investigation.”


Panetta also said he wants the Senate Armed Services Committee to act promptly on Obama’s nomination of Gen. Joseph Dunford to succeed Allen as commander in Afghanistan. That nomination was made several weeks ago. Dunford’s hearing is also scheduled for Thursday.


___


Associated Press writer Slobodan Lekic in Kabul, Afghanistan, contributed to this report.


Asia News Headlines – Yahoo! News



Read More..

Belize wants to quiz anti-computer virus guru McAfee in murder probe
















BELIZE CITY (Reuters) – Police in Belize want to question U.S. anti-computer virus software pioneer John McAfee in connection with the murder of a neighbor he had been quarrelling with, but they say he remains a person of interest at this time and is not a suspect.


McAfee, who invented the anti-virus software that bears his name, has homes and businesses in Belize, and is believed to have settled in the country sometime around 2010.













“He is a person of interest at this time,” said Marco Vidal, head of Belize’s police Gang Suppression Unit. “It goes a bit beyond that, not just being a neighbor.”


Police officers were looking for the software engineer, said Miguel Segura, the assistant commissioner of police.


Asked if McAfee was a suspect, he said: “At this point, no. Our job … is to get all the evidence beyond reasonable doubt that Mr A is the one that killed Mr B.”


“He (McAfee) … can assist the investigation, so there is no arrest warrant for the fellow,” added Segura, who heads the Criminal Investigation Branch.


McAfee’s neighbor, Gregory Viant Faull, a 52-year-old American, was found on Sunday lying dead in a pool of blood after apparently being shot in the head.


McAfee has been embroiled in controversy in Belize before.


His premises were raided in May after he was accused of holding firearms, though most were found to be licensed. The final outcome of the case is pending.


McAfee also owns a security company in Belize as well as several properties and an ecological enterprise.


Reuters was unable to contact McAfee on Monday.


Segura said McAfee had been at odds with Faull for some time. He accused his neighbor of poisoning his dogs earlier this year and filed an official complaint.


“There was some conflict there between (them) … prior to the death of the gentleman,” Segura said. “But those dogs didn’t have a post mortem to see if the toxicology would confirm what type of poison, if any.”


McAfee previously accused the police Gang Suppression Unit of killing his dogs during the May raid.


McAfee was one of Silicon Valley’s first entrepreneurs to amass a fortune by building a business off the Internet.


The former Lockheed systems consultant started McAfee Associates in 1989, initially distributing its anti-virus software as “shareware” on Internet bulletin boards.


He took the company public in 1992 and left two years later following accusations that he had hyped the arrival of a virus known as Michelango, which turned out to be a dud, to scare computer users into buying his company’s products.


(Reporting by Simon Gardner and Gabriel Stargardter in Mexico City and Jim Finkle; Editing by Kieran Murray and Todd Eastham)


Internet News Headlines – Yahoo! News



Read More..

U2′s Bono to urge U.S. politicians not to cut aid programs
















WASHINGTON (Reuters) – Irish rocker and anti-poverty campaigner Bono will appeal to Democrats and Republicans during a visit to Washington this week to spare U.S. development assistance programs from cuts as Congress tries to avert the looming “fiscal cliff” of tax hikes and spending reductions early next year.


The U2 lead singer’s visit comes as the Obama administration and congressional leaders try to forge a deal in coming weeks to avoid the economy hitting the “fiscal cliff” – tax increases and spending cuts worth $ 600 billion starting in January if Congress does not act.













Analysts say the absence of a deal could shock the United States, the world’s biggest economy, back into recession.


Kathy McKiernan, spokeswoman for the ONE Campaign, said Bono will hold talks with congressional lawmakers and senior Obama administration officials during the November 12-14 visit.


During meetings he will stress the effectiveness of U.S. foreign assistance programs and the need to preserve them to avoid putting at risk progress made in fighting HIV/AIDS, tuberculosis and malaria, she said.


Bono, a long-time advocate for the poor, will argue that U.S. government-funded schemes that support life-saving treatments for HIV/AIDS sufferers, nutrition programs for malnourished children, and emergency food aid make up just 1 percent of the U.S. government budget but are helping to save tens of millions of lives in impoverished nations.


The One Campaign would not elaborate which lawmakers and senior Obama administration officials Bono will meet.


On Monday, Bono will discuss the power of social movements with students at Georgetown University. He will also meet new World Bank President Jim Yong Kim for a web cast discussion on Wednesday on the challenges of eradicating poverty.


(Editing by W Simon)


Music News Headlines – Yahoo! News



Read More..

How To Tell If Gadgets Are Needlessly Complicated: The Mom Test
















This is a rant, of the grumpy-old-man variety.


Two weeks ago I was staying at my parents’ apartment because my home in New Jersey was without power, thanks to Hurricane Sandy.













“Oh, Sonny, I’m glad you’re here,” my mother told me when I arrived. “I need you to help me set up the DVD player.”


I love my mom to bits and pieces, but sometimes it’s like a bad sitcom with her: The tech writer son tries to help his mother (who still refers to the refrigerator as the “icebox,” by the way) do something he thinks is the easiest thing in the world but to her is akin to landing the Mars Rover.


We went into her bedroom. She had a television that was connected to a cable box and a DVD player—simple. Even the universal remote that came with her cable box was already programmed to work with the TV and DVD player. Miracle of miracles.


“See, Mom, you’re going to want to change inputs when you switch from cable to DVD,” I said.


“Change inputs?” she replied. “Can’t I just have it set to channel 3?”


This is what I’m talking about: My mother has that Reagan-era notion that you can set a channel of the TV to be an auxiliary input, like I used to do when I wanted to fire up the VHS and watch The Last Starfighter. Again.


“No, Mom. It’s really simple. Let me show you.” This is where things fell apart. But not because of my mom. “OK,” I began, “you’re going to use the cable box remote. Remember to push ‘DVD’ at the top of the remote to send commands to the DVD. You’ll then have to push ‘STB’ when you want to go back to cable, but to change the TV’s input, push ‘TV.’”


The cable box remote did have a “video source” button on it. And pushing it did call up the TV’s video source menu. And pushing “video source” repeatedly did allow one to cycle through the available sources. I reached “DVD,” selected it, and then looked for the “exit” button to close out the source menu.


Except my remote didn’t have an “exit” button. Or, it did, but it wasn’t mapped to the TV’s exit function. So the TV’s source menu just sat there—on top of my mother’s DVD of The Thin Man playing underneath.


“OK, Mom, looks like this remote can’t access all the functions on your TV, so we’re going to get the TV’s original remote,” I said. Even as the words were coming out of my mouth, I knew this wasn’t going to work.


“Seriously?” my mother asked. “Lemme get this straight: If I want to watch the goddamn Thin Man on the DVD, I have to first get the TV remote, find the source menu, switch to ‘DVD,’ then go back to the cable remote, select ‘DVD,’ press ‘play,’ but don’t forget to switch the remote back to ‘STB’ when I want to control the cable box? Something like that?”


“Um. Yeah, Mom.”


“What the hell happened to channel 3?”


Here’s the thing about my technophobic mother: She’s absolutely right. The tiny hoops we are asked to jump through give lie to the idea that technology is going to make our lives easier. In some cases it does (I never get lost in my car anymore, thanks to GPS; I’m never bored anymore, thanks to my smartphone), but there are glaring omissions.


TV manufacturers, can you please get it together? Can there be some common standards so my TV knows when I’ve put a disc in the DVD player, and it can ask me if I’d like to watch it now? Can remotes and devices talk to each other automatically, with full functionality, without the need to program them? Can someone please let me access any and all on-demand, streaming, or downloaded video without having to switch from my set-top box to Netflix (NFLX) or iTunes? Can I have a TV setup that I don’t have to explain how to use to house guests and babysitters? (“… sometimes the sound bar will turn itself off because it gets confused by a signal from the remote to the TV. Just use this remote to …”)


Face it, TV people: Your products are commodities. No one cares about your hardware. One display is virtually indistinguishable from another. But if one of you actually made it easier to use your product? Let me tell you something—it wouldn’t just be 65-year-old Jewish women on the Upper West Side of Manhattan who would be interested. We’d all line up for that.


Businessweek.com — Top News



Read More..

RIM to unveil new BlackBerry phones on Jan. 30.
















TORONTO (AP) — Research In Motion said Monday that it will hold an official launch event for its new BlackBerry 10 smartphones on Jan. 30. The new phones are seen as critical to RIM’s survival.


The Waterloo, Ontario-based company said Monday details on the much-delayed smartphones and their availability will be announced at the event.













The announcement comes as the company struggles in North America to hold onto customers who are abandoning BlackBerrys for flashier iPhones and Android phones.


RIM’s current software is still focused on email and messaging, and is less user-friendly, agile and robust than iPhone or Android. Its attempt at touch screens was a flop, and it lacks the apps that power other smartphones. RIM is hanging its hopes on the BlackBerry 10 software. It is thoroughly redesigned for the touchscreen, Internet browsing and apps experience that customers now expect. The Canadian company said the launch event will happen simultaneously in multiple countries.


Jefferies analyst Peter Misek called it a make-or-break product release and said the date of the launch event suggests a release date in mid- to late February or in March.


A full touchscreen device is expected to be released first followed shortly after by a physical keyboard version.


BGC Financial Partners analyst Colin Gillis said the new phones won’t be dead on arrival as some analysts have said because RIM hasn’t lost the corporate market completely.


“Is 10 going to be the solution to retain that marketplace? We’ll have to wait and see,” Gillis said. “It’s great they set a date, but the challenges are still formidable. It’s not an issue of initial demand. It’s an issue of sustained demand.”


Gillis noted that RIM’s launch of a tablet initially went OK but then demand fell sharply. RIM’s tablet, the Playbook, uses software on which the BlackBerry 10 will be based.


RIM said last month the new BlackBerrys are being tested by 50 wireless carriers around the world.


Thorsten Heins, who took over as CEO in January after the company lost tens of billions in market value, had vowed to do everything he could to release BlackBerry 10 this year but said in June that the timetable wasn’t realistic. Heins says he can turn things around with BlackBerry 10.


The new BlackBerrys will be released after the holiday shopping season and well after Apple’s launch of the iPhone 5, expected to be Apple’s biggest product introduction yet.


RIM’s platform transition is also happening under a new management team and as RIM lays off 5,000 employees as part of a bid to save $ 1 billion.


RIM was once Canada‘s most valuable company with a market value of more than $ 80 billion in 2008, but the stock has plummeted since, from over $ 140 per share to around $ 8. Its decline evokes memories of Nortel, another former Canadian tech giant, which declared bankruptcy in 2009.


Shares of RIM rose 20 cents, or 2.3 percent, to $ 8.74 in midday trading in New York after rising as high as $ 9.07 earlier.


Gadgets News Headlines – Yahoo! News



Read More..

U2′s Bono to urge U.S. politicians not to cut aid programs
















WASHINGTON (Reuters) – Irish rocker and anti-poverty campaigner Bono will appeal to Democrats and Republicans during a visit to Washington this week to spare U.S. development assistance programs from cuts as Congress tries to avert the looming “fiscal cliff” of tax hikes and spending reductions early next year.


The U2 lead singer’s visit comes as the Obama administration and congressional leaders try to forge a deal in coming weeks to avoid the economy hitting the “fiscal cliff” – tax increases and spending cuts worth $ 600 billion starting in January if Congress does not act.













Analysts say the absence of a deal could shock the United States, the world’s biggest economy, back into recession.


Kathy McKiernan, spokeswoman for the ONE Campaign, said Bono will hold talks with congressional lawmakers and senior Obama administration officials during the November 12-14 visit.


During meetings he will stress the effectiveness of U.S. foreign assistance programs and the need to preserve them to avoid putting at risk progress made in fighting HIV/AIDS, tuberculosis and malaria, she said.


Bono, a long-time advocate for the poor, will argue that U.S. government-funded schemes that support life-saving treatments for HIV/AIDS sufferers, nutrition programs for malnourished children, and emergency food aid make up just 1 percent of the U.S. government budget but are helping to save tens of millions of lives in impoverished nations.


The One Campaign would not elaborate which lawmakers and senior Obama administration officials Bono will meet.


On Monday, Bono will discuss the power of social movements with students at Georgetown University. He will also meet new World Bank President Jim Yong Kim for a web cast discussion on Wednesday on the challenges of eradicating poverty.


(Editing by W Simon)


Music News Headlines – Yahoo! News



Read More..

Cost becomes bigger question in treating heart disease
















LOS ANGELES (Reuters) – The cost of treating heart disease has become a key factor in decisions by U.S. cardiologists grappling with the nation’s No. 1 killer.


Record prices for drugs and devices, reduced reimbursement by insurance plans and the looming full implementation of the healthcare reform law are convincing doctors to consider not only novel treatments, but also how to get the most bang for the buck.













The trend was reflected at the annual scientific meeting of the American Heart Association, generally a forum for groundbreaking research on medications and devices to combat heart disease.


The conference for the first time last year featured an entire session on the economics of healthcare, including a study showing that eliminating drug co-payments for heart attack victims significantly reduced the chance that they would suffer another major cardiovascular problem.


The 2012 meeting, held last week in Los Angeles, included several dual presentations with companion studies on the economic impact of a drug or therapy as well as its safety and effectiveness.


“We have an unsustainable economic model in healthcare delivery in the U.S.,” said Dr. Elliott Antman, professor of medicine at Harvard Medical School and chairman of the AHA Scientific Sessions Committee. “We all have to be conscious of ways we can be more cost efficient, and that includes understanding what the big breakthroughs mean in terms of cost.”


Heart disease is the leading cause of death for both men and women in the United States, accounting for one of every four deaths, according to the Centers for Disease Control and Prevention.


It also is very expensive. AHA estimates that annual U.S. medical costs of cardiovascular disease will reach $ 800 billion by 2030 – nearly triple the $ 272 billion spent in 2010.


“Rising costs of medical care make it very pertinent for us to assess value,” said Dr. Mark Hlatky, director of the cardiovascular outcomes research center at Stanford University.


President Barack Obama’s Affordable Care Act, which has now survived a challenge in the Supreme Court and a presidential election, is structured to reward quality of care, not the traditional fee-for-service model that can result in unnecessary treatment.


But the equation is not always simple.


One study presented at the AHA meeting showed that diabetics with diseased arteries not only fared better if they underwent bypass surgery rather than a less expensive stent procedure, but the surgery was also more cost effective.


Researchers, funded by the National Institutes of Health, found that up-front costs for bypass surgery and hospitalization were about $ 8,600 higher than costs for stent patients. But more stent patients either died or needed repeat artery clearing, while those who had surgery lived longer, higher-quality lives, resulting in lower, long-term healthcare spending for them.


Another study found that angioplasty to clear blocked arteries costs more at hospitals not equipped for emergency heart surgery, due mainly to follow-up costs. Elective angioplasty is becoming increasingly common at hospitals that do not conduct more complicated heart procedures.


“Surprisingly, there was no difference in procedure cost,” said Dr. Eric Eisenstein, lead author of the study and assistant professor of medicine at Duke University Medical School in North Carolina. “We did find a difference in follow-up cost.”


New research paid for by Johnson & Johnson, one of the makers of the new anti-clotting drug Xarelto, showed that the costs of a heart attack, angina, or chest pain go well beyond actual hospital care.


The study, led by Robert Page, a clinical specialist in the division of cardiology at the University of Colorado School of Pharmacy in Aurora, Colorado, found that every short-term disability claim for acute coronary syndrome cost employers nearly $ 8,000, and each long-term claim carried a price tag of more than $ 52,000.


Annual healthcare costs for each worker, including out-of-pocket expenses, totaled nearly $ 8,200 during the four-year period studied.


About half of all patients with acute coronary syndrome – a term used to describe conditions in which the blood supply to the heart is blocked – are working adults under the age of 65, Page said. That means the burden for their care will more likely fall on employers and employee co-payments rather than on the Medicare system.


The AHA estimates the rate of coronary heart disease in the United States will increase by 16 percent between 2010 and 2030.


Xarelto is one of three new blood-thinning medicines that offer potential advantages over older drugs to prevent strokes and other dangerous conditions caused by blood clots. Another is Pradaxa, made by Germany’s Boehringer Ingelheim.


“These drugs are expensive. They cost more than warfarin which is relatively cheap to use,” said Dr. Stuart Connolly, director of the cardiology division at McMaster University in Ontario, Canada. “Cost-effectiveness studies have been favorable. The reason is that even though purchase of the drug is not cheap, there are savings from preventing ischemic strokes.”


Even so, physicians can face significant hurdles to secure insurance coverage for patients they think need to be on a new, more expensive drug.


“It is a cost firewall,” Antman said, explaining that it can take considerable time for him to talk to insurance telephone operators, claims supervisors and, eventually, medical directors to secure coverage for a patient.


(Additional reporting by Bill Berkrot; Editing by Martin Howell and Leslie Adler)


Medications/Drugs News Headlines – Yahoo! News



Read More..

Probe into alleged gas price fix

















Allegations of manipulation of UK wholesale gas prices are being investigated by the Financial Services Authority (FSA) and Ofgem.













The investigations by the FSA, the UK’s financial watchdog, and energy regulator Ofgem follow claims by a whistleblower.


Energy Secretary Edward Davey said he was “extremely concerned about the allegations”.


“The government takes alleged abuse in our markets very seriously,” he added.


Two of the UK’s big six energy suppliers have released statements to deny any involvement.


EDF Energy said it “does not participate in loss-leading trading activity and considers it to be against existing market regulation”.


It added: “We make information likely to impact market price formation publicly available on our website in compliance with the European Union’s regulation on energy market integrity and transparency.”


NPower said: “There is an explicit commitment in our code of conduct to comply with all laws and regulations.”


Mr Davey said he would keep in close contact with the two investigations.


He will make a statement on the issue in the House of Commons on Tuesday.


The whistleblower worked at ICIS Heron, a financial information company that publishes energy price reports.


ICIS Heron said it “detected some unusual trading activity on the British wholesale gas market on 28 September 2012, which it reported to energy regulator Ofgem in October”.


It added: “The cause of the trading pattern, which involved a series of deals done below the prevailing market trend, has not yet been established.”


BBC News – Business



Read More..

Canada seen needing to spell out rules for natural gas projects
















CALGARY, Alberta (Reuters) – The fate of a handful of liquefied natural gas projects planned for Canada’s Pacific coast may depend on the Canadian government‘s willingness to spell out rules for foreign investment in the country’s energy sector, according to a study released on Thursday.


Apache Corp, Royal Dutch Shell Plc, Petronas, BG Group Plc and others are in the planning stages for LNG projects that would take gas from the rich shale fields of northeastern British Columbia and ship it to Asian buyers.













But the federal government’s decision last month to stall the C$ 5.2 billion ($ 5.2 billion) bid by Malaysia’s state-owned Petronas C$ 5.2 billion for Canada‘s Progress Energy Resources Corp could lessen the appetite of Asian buyers for Canadian LNG, energy consultants Wood Mackenzie said.


“Some potential off-takers of Canadian LNG like the idea … because it’s perceived as having low political risk, and another reason is because they see the potential for investment opportunities,” said Noel Tomnay, head of global gas at the consultancy.


“If there are going to be restrictions on how they access those opportunities, if acquisitions are closed to them, then clearly that would restrict the attractiveness of those opportunities. If would-be Asian investors thought that corporate acquisitions were an avenue that was not open to them then Canadian LNG would become less attractive.”


The Canadian government is looking to come up with rules governing corporate acquisitions by state-owned companies and has pushed off a decision on the Petronas bid as it considers whether to approve the $ 15.1 billion offer for Nexen Inc from China’s CNOOC Ltd.


Exporting LNG to Asia is seen as a way to boost returns for natural-gas producers tapping the Montney, Horn River and Liard Basin shale regions of northeastern British Columbia.


Though Wood Mackenzie estimates the fields contain as much as 280 trillion cubic feet of gas, they are far from Canada’s traditional U.S. export market, while growing supplies from American shale regions have cut into Canadian shipments.


Because the region lacks infrastructure, developing the resource will be expensive, requiring new pipelines and multibillion-dollar liquefaction.


Still Wood Mackenzie estimates that the cost of delivery into Asian markets for Canadian LNG would be in the range of $ 10 million to $ 12 per million British thermal units, similar to competing projects in the United States and East Africa.


($ 1 = $ 1.00 Canadian)


(Reporting by Scott Haggett; Editing by Leslie Adler)


Canada News Headlines – Yahoo! News



Read More..

Vt. Mom Begs FDA: Save My Other Son
















Jenn McNary, a mother of six from Saxtons River, Vt., is desperate.


Both her boys have Duchenne muscular dystrophy, but only her 10-year-old Max has access to a wonder drug that appears to be reversing the symptoms of this deadly disease.













His 13-year-old brother Austin is languishing in a wheelchair while Max has been able to take the drug eteplirsen through a highly successful clinical trial.


After 60 weeks on an IV infusion, Max was able to participate in a three-mile Halloween walk.


“It’s the first time ever — he’s never been able to walk that far. He’s always gone with a wheelchair, even as a toddler,” said McNary, 32. “He actually doesn’t look like a Duchenne kid at all. And his balance is great.”


“People all over the world are calling it a miracle,” she said of the drug.


Now, McNary has written petitioned the Food and Drug Administration to give accelerated approval of the medication, the fastest way to help Austin and other boys with the disease.


Both boys, whose last name is Leclair, have the same gene mutation that the drug targets and will eventually kill them. Austin was diagnosed at 3 and Max at 3 months.


McNary and her husband Craig are also raising four other healthy children in a second marriage.


There is no cure for Duchenne muscular dystrophy. Until now, doctors have only been able to use steroids, which just temporarily delay the inevitable loss of muscle strength.


“My brother says he’s doing it for me, that he’s trying really hard,” Austin told ABCNews.com in August. “That’s why he wanted to do it.”


Austin was not allowed to participate in the clinical trial because one of the inclusion criteria was that he be able to complete a six-minute walk.


“This has been a bitter-sweet journey for us,” McNary wrote in a letter to the FDA this week. “As we watch Max get better, we also watch his older brother, Austin, 13, get worse. He suffers, silently, as his disease progresses.”


Duchenne muscular dystrophy affects one in 3,500 male births, about 20,000 children in the United States and 300,000 worldwide, according to Cure Duchenne, one of three organizations that have funded the clinical trial.


The muscular disease strikes between the ages of 3 and 5 as boys progressively lose their ability to walk. Eventually, they are wheelchair bound, their upper body strength fails, and, like Austin, they eventually cannot raise their arms to feed themselves.


Later, their breathing is affected and they require tracheotomies and breathing assistance. Eventually, the heart and lungs fail.


Parents of children who were in the clinical trial of eteplirsen at Nationwide Children’s Hospital in Columbus are calling it a “wonder drug.”


According to McNary, all 12 children in the double-blind study received “some benefit” from the drug. It has no known side effects.


“Even two boys who stopped walking before taking it have stronger upper bodies and their hearts are strong,” she said. “They have progressed to stable.”


Muscular Dystrophy Drug Could Stabilize Disease


If this exon-skipping drug is approved, she estimates 15 percent of boys with Duchenne could be helped, those with the type that skips exon 51. As a class of drugs, they could up to 85 percent of boys with the disease.


Stock prices for its manufacturer, Sarepta Therapeutics. , have soared.


If Sarepta Therapeutics can get accelerated approval, the drug could be available in six to nine months, according to McNary. Otherwise, the wait could be four or five years — too late for Austin.


“We are very encouraged by the data we have seen to date,” said Chris Garabedian, president and CEO of Sarepta Therapeutics, which makes the drug and is pressing the FDA to take action.


“If we start using the drug earlier in patients, we might be able to stabilize whatever state they are in for a longer period of time,” said Garabedian. “We are not going to end up creating Olympic athletes from this drug, but we are encouraged this could really halt or slow the progression.”


McNary is reaching out to media and online petition sites to encourage as many people as possible to write letters of support to the FDA.


But as she waits approval, Austin gets weaker. In the last few months, he has lost all upper body control and must be lifted 100 percent of the time.


Just recently, he was diagnosed with sleep apnea and must go on a nighttime machine to keep his lungs inflated.


Austin keeps his spirits high, according to McNary.


On Halloween, he dressed his wheelchair up as a hot dog stand, carrying his dachshund in a cloth bun. And just recently, his father and uncle took him hunting. They held up the gun for Austin and he shot his first buck — an eight-pointer.


McNary is convinced that if the FDA can move on approving the drug that has healed Max, it can also help Austin.


Until then, he’s “hanging in there,” she said. “He has a huge zest for life.”


Also Read
Medications/Drugs News Headlines – Yahoo! News



Read More..